Comparing BioHarvest Sciences (NASDAQ:BHST) and Haleon (NYSE:HLN)

BioHarvest Sciences (NASDAQ:BHST) and Haleon (NYSE:HLN) are both consumer staples companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Insider and Institutional Ownership

6.7% of Haleon shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

BioHarvest Sciences has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Haleon has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500.

Valuation and Earnings

This table compares BioHarvest Sciences and Haleon”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioHarvest Sciences	$35.48 million	0.87	-$11.14 million	($0.52)	-3.02
Haleon	$11.15 billion	3.47	$2.20 billion	$0.39	22.53

Haleon has higher revenue and earnings than BioHarvest Sciences. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Haleon, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for BioHarvest Sciences and Haleon, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1	0	2	0	2.33
Haleon	1	4	3	2	2.60

BioHarvest Sciences currently has a consensus target price of $6.50, indicating a potential upside of 314.01%. Haleon has a consensus target price of $4.90, indicating a potential downside of 44.22%. Given BioHarvest Sciences’ higher probable upside, analysts clearly believe BioHarvest Sciences is more favorable than Haleon.

Profitability

This table compares BioHarvest Sciences and Haleon’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-31.21%	-58.30%	-25.60%
Haleon	N/A	N/A	N/A

Summary

Haleon beats BioHarvest Sciences on 12 of the 14 factors compared between the two stocks.

About BioHarvest Sciences

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.